Previous 10 | Next 10 |
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesda...
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Margaret Olinger - Chief Commercial Offic...
Amylyx Pharmaceuticals press release ( NASDAQ: AMLX ): Q3 GAAP EPS of -$0.92 beats by $0.04 . Revenue of $0.35M (+20.7% Y/Y) beats by $0.27M . For further details see: Amylyx Pharmaceuticals GAAP EPS of -$0.92 beats by $0.04, revenue of $0.35M beats by $0...
˗ RELYVRIO™ (sodium phenylbutyrate and taurursodiol) approved for the treatment of ALS in adults and now commercially available in the U.S., representing second product launch for Amylyx worldwide ˗ Commercial launch of ALBRIOZA™ (sodium phenylbutyr...
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced it will report third quarter 2022 financial results on Thursday, November 10, 2022 following the close of the U.S. financial markets. Amylyx’ senior management team will host a conference call and audio webcast...
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common stock at a public offering price of $32.00 per share, which includes the exercise in full by the underwrit...
Amylyx Pharmaceuticals ( NASDAQ: AMLX ) has priced an upsized underwritten public offering of 6,693,750 shares of its common stock at a public offering price of $32.00/share. All of the shares of common stock are being offered by Amylyx. Underwriters are granted a 30-d...
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the pricing of an upsized underwritten public offering of 6,693,750 shares of its common stock at a public offering price of $32.00 per share. All of the shares of common stock are being offered by Amylyx. Amylyx ...
Amylyx Pharmaceuticals ( NASDAQ: AMLX ) on Tuesday announced the launch of a public stock offering of up to 6M shares. All the shares in offering are being put up by the company. AMLX also expects to grant the underwriters a 30-day option to buy up to an additional 900...
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the launch of an underwritten public offering of 6,000,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”). All of t...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...